NR1H4 and Hepatic fibrosis: Because HSC activation is a hallmark of liver fibrosis, we hypothesized that the differentiated responses of quiescent and activated HSCs to FXR agonists may underlie the discrepancy between prophylactic and therapeutic treatments.